Phase II biomarker trial of a multimarker diagnostic for ovarian cancer

Edgell, Tracey, Martin-Roussety, G., Barker, G., Autelitano, D. J., Allen, D., Grant, P. and Rice, G. E. (2010) Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. Journal of Cancer Research and Clinical Oncology, 136 7: 1079-1088. doi:10.1007/s00432-009-0755-5

Author Edgell, Tracey
Martin-Roussety, G.
Barker, G.
Autelitano, D. J.
Allen, D.
Grant, P.
Rice, G. E.
Title Phase II biomarker trial of a multimarker diagnostic for ovarian cancer
Journal name Journal of Cancer Research and Clinical Oncology   Check publisher's open access policy
ISSN 0171-5216
Publication date 2010-07
Sub-type Article (original research)
DOI 10.1007/s00432-009-0755-5
Volume 136
Issue 7
Start page 1079
End page 1088
Total pages 10
Editor Klaus Höffken
Place of publication Heidelberg, Germany
Publisher Springer
Collection year 2011
Language eng
Formatted abstract
Purpose: The primary hypothesis to be tested in this study was that the diagnostic performance (as assessed by the area under the receiver operator characteristic curve, AUC) of a multianalyte panel to correctly identify women with ovarian cancer was significantly greater than that for CA-125 alone.

Methods: A retrospective, case–control study (phase II biomarker trial) was conducted that involved 362 plasma samples obtained from women with ovarian cancer (n = 150) and healthy controls (n = 212). A multivariate classification model was developed that incorporated five biomarkers of ovarian cancer, CA-125; C-reactive protein (CRP); serum amyloid A (SAA); interleukin 6 (IL-6); and interleukin 8 (IL-8) from a modelling cohort (n = 179). The performance of the model was evaluated using an independent validation cohort (n = 183) and compared with of CA-125 alone.

Results: The AUC for the biomarker panel was significantly greater than the AUC for CA-125 alone for a validation cohort (p < 0.01) and an early stage disease cohort (i.e. Stages I and II; p < 0.01). At a threshold of 0.3, the sensitivity and specificity of the multianalyte panel were 94.1 and 91.3%, respectively, for the validation cohort and 92.3 and 91.3%, respectively for an early stage disease cohort.

Conclusions: The use of a panel of plasma biomarkers for the identification of women with ovarian cancer delivers a significant increase in diagnostic performance when compared to the performance of CA-125 alone.
© The Author(s) 2010. This article is published with open access at
Keyword Ovarian cancer
Multivariate classification
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 36 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 40 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 18 Feb 2011, 11:13:42 EST by Caroline Irle on behalf of !NON-HERDC